Cancer Discov. 2017 Jul;7(7):660. doi: 10.1158/2159-8290.CD-NB2017-070. Epub 2017 May 18.
The FDA recently expanded label indications for regorafenib to include treating patients with advanced hepatocellular carcinoma whose disease has progressed on the standard of care, sorafenib. Until now, these patients have had no other treatment options. Regorafenib is the first drug to be approved for liver cancer in a decade.
美国食品药品监督管理局（FDA）最近扩大了regorafenib 的标签指示，将其用于治疗在标准治疗方案（sorafenib）下疾病进展的晚期肝细胞癌患者。到目前为止，这些患者没有其他治疗选择。regorafenib 是十年来批准用于肝癌的第一种药物。
